Roche Holding AG bullish scenario:The technical figure Triangle can be found in the daily chart in the German company F. Hoffmann-La Roche AG (ROG.vx). Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. Roche is the fifth largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. The Triangle broke through the resistance line on 07/09/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 10 days towards 333.65 CHF. Your stop-loss order, according to experts, should be placed at 311.75 CHF if you decide to enter this position.
Roche announced the launch of the Digital LightCycler System, Roche’s first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
The Digital LightCycler System will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
AMS- Target 11,50 till end of 2022The chart looks good. I think we might have seen the bottom here. we should not fall below that down trendline on a daily base. with strong markets we could skip (1) and go directly to the 9,50 area. after that we should retest the resist at 8,70 area and climb to the target at about 11,50. from there it will be a bit more difficult as we meet the first fib resist.
Givaudan SA (GIVN.vx) bullish scenario:The technical figure Falling Wedge can be found in the Swiss company Givaudan SA (GIVN.vx) at daily chart. Givaudan is a Swiss multinational manufacturer of flavours, fragrances and active cosmetic ingredients. As of 2008, it is the world's largest company in the flavour and fragrance industries. The Falling Wedge has broken through the resistance line on 05/07/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 42 days towards 3 840 CHF. Your stop-loss order according to experts should be placed at 3 025 CHF if you decide to enter this position.
Fragrance and flavour maker Givaudan confirmed its mid-term targets and said it would keep raising prices this year to offset higher input costs after like-for-like sales rose 4.6% in the first quarter. Givaudan confirmed its mid-term target of 4-5% underlying sales growth and free cash flow of at least 12% on average over a five-year cycle. Group sales were 1.78 billion Swiss francs ($1.91 billion), a 6.4% rise in Swiss francs.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
Sonova Holding AG bearish scenario:The technical figure Descending Triangle can be found in the Swiss company Sonova Holding AG (SOON.vx) at daily chart. Sonova Holding AG is an internationally active Swiss company headquartered in Stäfa that specializes in hearing care (hearing instruments, cochlear implants, wireless communication). It is one of the largest providers in the sector worldwide. The group operates through its core business brands Phonak, Unitron, Hansaton, Advanced Bionics and AudioNova. The Descending Triangle has broken through the support line on 17/06/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 32 days towards 259.20 CHF. Your stop loss order according to experts should be placed at 351.20 CHF if you decide to enter this position.
Sonova said it had faced shortages of microelectronic components towards the end of the first half. The disruptions to the global economy during the pandemic have upset supply chains across continents, causing shortages of goods and services, including microelectronic components used for hearing aid.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
Novartis AG (NOVN.vx) bearish scenario:The technical figure Triangle can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine (Lamisil), deferasirox (Exjade), and others. The Triangle has broken through the support line on 03/05/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 12 days towards 80.160 CHF. Your stop loss order according to experts should be placed at 87.480 CHF if you decide to enter this position.
Novartis said earnings and sales rose in the first quarter of the year, boosted by its key drugs, including heart failure treatment Entresto. Net income was $2.2 billion, up from $1.8 billion in the same quarter the previous year, on sales that grew to $12.53 billion from $12.41 billion. Analysts expected sales of $12.62 billion.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
Nestle Europe Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series
Focus: Worldwide
By Sun Storm Investment Research & NexGen Wealth Management Service
A Profit & Solutions Strategy & Research
Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures |
USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India
Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision.
#debadipb #profitsolutions
Geberit - GEBN• Triangle formation with a decreasing volume to the end of the formation
• Negative outbreak in the last trading session
• Outbreak not supported by higher volume, which is a weak signal for the outbreak
• MACD continuation looks weaker for the next trading sessions, which could support the outbreak
• The next trading sessions will show if the outbreak will be confirmed
• Price Target appr. at CHF 495
Novartis (NOVN.vx) bullish scenario:The technical figure Double Bottom can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), deferasirox (Exjade), and others. The Double Bottom has broken through the resistance line on 07/04/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 29 days towards 86.88 CHF. Your stop-loss order according to experts should be placed at 72.50 CHF if you decide to enter this position.
Novartis CEO Vas Narasimhan is continuing his shake-up of the giant Swiss drugmaker, announcing a corporate restructuring on Monday that the company says will simplify its organizational chart and bring more than $1 billion in annual savings.
Novartis AG NVS announced that the FDA has approved its kinase inhibitor, Vijoice (alpelisib), for the treatment of patients aged two years and above with severe manifestations of PIK3CA-Related Overgrowth Spectrum (“PROS”), requiring systemic therapy. Per the company, following the nod, Vijoice became the first FDA-approved therapy to treat PROS, which includes rare conditions where overgrowths and blood vessel anomalies occur.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
FHZN - The power of elliot waves | Volume 2The zurich airport is tough, but in the coming months this toughness will be tested once again! SIX:FHZN
Our last analysis on this share was published on January 12, in which we warned about a potential sell-off.
In this analysis we highlighted the importance of the wedge formation to our subscribers. In the last days the stock fell by more than -20% and we have now left this formation.
Today zurich airport published its earnings and based on them we can evaluate the progress of the company.
The airport was able to slightly reduce its net loss in the past year but disappointed investors with lower revenues than expected .
Revenues were just under 680 million , which is about half of what they were before the Corona crisis. The management announced that a full recovery to the pre-crisis level of 2019 is not expected until the end of 2025. Investors will have to be patient with the company and as most assumed there won't be a dividend payout again this year. This however gives the management the opportunity to direct the money to where it's most needed.
Overall, the airport is recovering in small steps from the shock of the Corona crisis.
The upcoming years will bring further difficulties, but the management will concentrate on navigating the company back to profitability.
Technical explanation of the elliot wave structure:
As mentioned above, the share price has fallen by almost -20% since we last warned of a sell-off. We as Mendenmein Capital see this as another confirmation of our calculations.
Nevertheless, we assume that the share has now expanded a first downward impulse in the white wave (1) and in the coming weeks a slight recovery must be expected in the white wave (2). This wave will lay the foundation for further sell-offs and the target for the next year is located at just 95 swiss francs. The white wave (3) should be able to reach this target without any problems.
After a short recovery in the white wave (4), a final wave (5) will continue to correct towards our final target of 80 swiss francs. We assume that this downward impulse will occupy us in the coming months and years.
In the long term however, we are extremely bullish and the formations of the last years point towards a very large wave I / wave II super cycle. This means that we have a multi-year bull market ahead of us after the completion of wave II, our subscribers are familiar with this term by now. The long-term price target for this stock is 450.- and we at Mendenmein Capital are extremely confident in our optimistic views.
On our website investors can learn more about the zurich airport share and other stocks! www.mendenmein-capital.com
Disclaimer:
According to legal regulations, Mornau-Research is not a certified or legally recognized financial advisor and any transactions based on published content are at your own risk.
Mornau-Research cannot be held liable for any losses whatsoever according to the legal regulations in it's country of residence.
===============================================================================================================
If you have questions related to a specific stock or the Elliot Wave theory, feel free to contact us.
Trading Idea - #SWATCHSELL Limit Order!
ENTRY: 275 CHF
TARGET: 208 CHF (profit 23%)
STOP: 294 CHF
I assume that the price of the SWATCH share can recover in the short term. This would go up to the POI level of CHF 274.
As SWATCH has become heavily dependent on the Chinese market and the Corona fear continues to dominate the markets, further pressure on the share is to be expected.
ABBN - ShortABB broke the lower boundary of the trend channel. Rebound to the channel possible with target in the marked resistance area
________
🚀 Follow for daily posts
🎯 About my posts: They are kept self-explanatory in order to avoid overcomplicating and confusion. Mostly price signals and trend analysis combined with chart patterns.
Disclaimer: This is not an investment advice
Lonza - LONN• Strong correction in the last days
• Nice support at 644.6/652
• In the middle of the correction period there is a small flag which marked the midpoint of the move
• Does the support hold at 644.6/652 or do we see a further correction to the next support at 610.40/623.8?
• In my point of view an interesting level to build up a small position and waiting for the next earning publications on January 26